Professor Anna Schuh, Dr Richard Dillon and Dr Angela Hamblin will discuss the importance of the cytogenetic, molecular and genomic testing that guide AML directed treatment. They will also provide an update of diagnostic developments that will influence clinical practice in the future.

The webinar is intended for healthcare professionals and healthcare laboratory scientists and CPD accreditation has been granted, in principle.

There will be an opportunity to ask the panelists questions on cytogenetic, molecular and genomic testing and their relevance in AML treatment during Q&A sessions at the end of each presentation, as well as at the panel discussion at the end of the webinar.

View the full agenda and sign up via the registration page.